← Leaderboards
Payel Jhoom Roy
Washington University
$1,151,077
Attributed
$2,302,154
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2023–25$2M$1.5M$1M$500K$0
'23
'24
'25
Funding mix
By agency
NIH$2,302,154 · 2
By mechanism
R01$1,884,492 · 1
R21$417,662 · 1
Top collaborators
- Anne Mobley Butler2 shared
- Michael Joseph Durkin2 shared
Most similar at Washington University
Same institution · by research overlap
- Anne Mobley Butler$6,591,827
- Allison Willis$6,981,326
- Joseph P Culver$22,566,427
- Tamara G Hershey$23,064,451
- Clay F. Semenkovich$38,041,096
Others in their field
Other Rising Stars on “Methodology”
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Jeffrey Leintz · National Opinion Research Center$40,628,545
- David Annett · Information Management Services, Inc.$35,571,865
- Cynthia M Visness · Rho Federal Systems Division, Inc.$14,006,776
- Songthip T. Ounpraseuth · Univ Of Arkansas For Med Scis$10,363,762
- Suma Babu · Massachusetts General Hospital$9,819,674
Research focus
MethodologyMethadoneDentalFormulationInnovationMedication SafetyComparative SafetyData SetEtiologyEvaluationHealth Services ResearchInjectableMedicalMedication For Opioid Use DisorderCase StudyAdverse EventCharacteristicsAddictionAccountingCommunicationBuprenorphineComparativeHealth Care Service UtilizationMortality
Grant awards (4)
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach$609,370
R01 · FY2025 · DE · contact PI
Oral Health Utilization and Outcomes Among Patients on Medications for Opioid Use Disorder$174,939
R21 · FY2024 · DA
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach$1,275,122
R01 · FY2023 · DE · contact PI
Oral Health Utilization and Outcomes Among Patients on Medications for Opioid Use Disorder$242,723
R21 · FY2023 · DA